CONTENTS:
- In Memoriam: Roland R. Griffiths (July 19, 1946-October 16, 2023). Henningfield J.E., Belouin S.J., Yaden D.B., Urrutia J., Anderson B.T., Berger A., et al., p. 299-300.
- Psilocybin's potential mechanisms in the treatment of depression: A systematic review. Lee H.J., Tsang V.W., Chai B.S., Lin M.C., Howard A., Uy C., et al., p. 301-315.
- Psychedelic experiences after bereavement improve symptoms of grief: The influence of emotional breakthroughs and challenging experiences. Low F., Earleywine M., p. 316-323.
- Health benefits and positive acute effects of psilocybin consumption: A quantitative textual analysis of user self-reported data. Bienemann B., Barbosa A.R., Cruz L., Multedo M., Mograbi D., p. 324-332.
- Associations between kratom-related state policy environments and kratom use in a nationally representative population in the United States. Ellis M.S., Buttram M.E., Forber A., Black J.C., p. 333-341.
- Sex moderates associations between dimensions of emotion dysregulation and problematic cannabis use. Cavalli J.M., Cservenka A., p. 342-352.
- Exclusive therapeutic use of cannabis in a large sample of daily cannabis users in France: A cross-sectional survey. Bastien M., Mezaache S., Donadille C., Martin V., Appel L., Lebrun M., et al., p. 353-363.
- Effectiveness of buprenorphine (naloxone) for opioid dependence does not differ across opioid categories: a retrospective cohort study from India. Ghosh A., Shaktan A., Basu D., Bn S., Naik S.S., Mattoo S.K., p. 364-372.
- Caregivers' attitudes toward treatment length for persons in Swedish opioid agonist treatment. A qualitative interview study. Nehlin C., Brander C.W., Öster C., p. 373-379.
- Pregabalin qualitative detection in Turkish forensic cases between 2017 to 2018. Teker C., Aslan R., Ipekçi C., Tokdemir M., Akgür S.A., p. 380-386.
- The effects of neighborhood disorder on polydrug use: Examining depressive symptoms and deviant peer association as mediating mechanisms. Wojciechowski T., p. 387-396.
- Risk and protective factors associated with drug use in healthcare professionals: A systematic review. Medina-Martinez J., Alino M., Vazquez-Martinez A., Villanueva-Blasco V.J., Cano-Lopez I., p. 397-411.
- Risk for ecstasy use disorder and other substance use among international users of recreational ecstasy/Molly/MDMA. Haug N.A., Wadekar R., Barry R., Sottile J., p. 412-421.
- Examining symptoms of stimulant misuse and community support among members of a recovery-oriented online community. Kasson E., Filiatreau L.M., Davet K., Kaiser N., Sirko G., Bekele M., et al., p. 422-432.
- Outcomes among sober living house residents who relapse: Role of recovery capital. Polcin D.L., Mahoney E., Witbrodt J., Subbaraman M., Mericle A.A., p. 433-441.